Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations
across multiple cancer types including both solid and hematologic malignancies has …

Simple Summary Chondrosarcomas are cartilage tumours that often harbour a mutation in
one of the isocitrate dehydrogenase (IDH) genes. IDH mutations are important drivers at the …

BRD4, a member of the bromodomain and extraterminal domain (BET) family and an
important epigenetic reader, has emerged as an attractive oncology target …

Cholangiocarcinoma (CCA) comprises a heterogeneous collection of malignancies arising
within the biliary tract, characterized by late diagnosis, innate chemoresistance, and …

Despite advances in treatment, the prognosis for glioma patients remains poor.
Bromodomain-containing protein 4 (BRD4), a member of the bromodomain and …

Cholangiocarcinoma is a primary malignancy of the biliary tract characterized by late and
unspecific symptoms, unfavorable prognosis, and few treatment options. The advent of next …

Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer arising from the bile ducts
with a need for earlier diagnosis and a greater range of treatment options. KRAS/NRAS …

Purpose: Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited
therapeutic options. Preclinical models focused on unresectable metastatic CCA are …

Cholangiocarcinoma (CCA) is a highly aggressive biliary tree malignancy with intrahepatic
and extra-hepatic subtypes that differ in molecular pathogeneses, epidemiology, clinical …